NASDAQ:VSAR - Versartis Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.05 -0.05 (-2.38 %) (As of 07/19/2018 02:05 AM ET)Previous Close$2.10Today's Range$2.00 - $2.1052-Week Range$1.35 - $22.10Volume113,628 shsAverage Volume520,995 shsMarket Capitalization$72.16 millionP/E Ratio-0.85Dividend YieldN/ABeta2.03 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California. Receive VSAR News and Ratings via Email Sign-up to receive the latest news and ratings for VSAR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:VSAR CUSIPN/A Webwww.versartis.com Phone650-963-8580 Debt Debt-to-Equity Ratio0.09 Current Ratio21.29 Quick Ratio21.29 Price-To-Earnings Trailing P/E Ratio-0.85 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$40,000.00 Price / Sales1,849.10 Cash FlowN/A Price / CashN/A Book Value$2.31 per share Price / Book0.89 Profitability EPS (Most Recent Fiscal Year)($2.41) Net Income$-84,970,000.00 Net MarginsN/A Return on Equity-84.63% Return on Assets-53.05% Miscellaneous Employees28 Outstanding Shares36,080,000Market Cap$72.16 Versartis (NASDAQ:VSAR) Frequently Asked Questions What is Versartis' stock symbol? Versartis trades on the NASDAQ under the ticker symbol "VSAR." How were Versartis' earnings last quarter? Versartis Inc (NASDAQ:VSAR) announced its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.86) by $0.61. View Versartis' Earnings History. When is Versartis' next earnings date? Versartis is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Versartis. What price target have analysts set for VSAR? 9 brokers have issued 1-year price objectives for Versartis' stock. Their forecasts range from $3.00 to $14.00. On average, they anticipate Versartis' share price to reach $5.1250 in the next year. This suggests a possible upside of 150.0% from the stock's current price. View Analyst Ratings for Versartis. What is the consensus analysts' recommendation for Versartis? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Versartis in the last year. There are currently 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Are investors shorting Versartis? Versartis saw a drop in short interest in the month of June. As of June 29th, there was short interest totalling 936,082 shares, a drop of 53.3% from the June 15th total of 2,004,665 shares. Based on an average daily volume of 950,622 shares, the short-interest ratio is presently 1.0 days. Currently, 3.2% of the company's stock are short sold. View Versartis' Current Options Chain. Who are some of Versartis' key competitors? Some companies that are related to Versartis include Biofrontera (BFRA), Athersys (ATHX), Synlogic (SYBX), Zafgen (ZFGN), Axovant Sciences (AXON), Kadmon (KDMN), DURECT (DRRX), Ovid Therapeutics (OVID), Avadel Pharmaceuticals (AVDL), resTORbio (TORC), Avid Bioservices (CDMO), Neptune Technologies & Bioressources (NEPT), REDHILL BIOPHAR/S (RDHL), Galmed Pharmaceuticals (GLMD) and Cue Biopharma (CUE). Who are Versartis' key executives? Versartis' management team includes the folowing people: Mr. Jay P. Shepard, CEO, Pres & Director (Age 60)Ms. Tracy M. Woody, Chief Commercial Officer (Age 48)Dr. Jeffrey L. Cleland, Co-Founder (Age 53)Dr. Joshua Silverman Ph.D., Co-FounderMr. Kevin Haas, VP of Fin. (Age 53) Has Versartis been receiving favorable news coverage? Press coverage about VSAR stock has trended somewhat positive on Wednesday, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Versartis earned a news sentiment score of 0.01 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.10 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days. How do I buy shares of Versartis? Shares of VSAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Versartis' stock price today? One share of VSAR stock can currently be purchased for approximately $2.05. How big of a company is Versartis? Versartis has a market capitalization of $72.16 million and generates $40,000.00 in revenue each year. The biopharmaceutical company earns $-84,970,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Versartis employs 28 workers across the globe. How can I contact Versartis? Versartis' mailing address is 1020 Marsh Rd, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-963-8580 or via email at [email protected] MarketBeat Community Rating for Versartis (NASDAQ VSAR)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 253 (Vote Outperform)Underperform Votes: 176 (Vote Underperform)Total Votes: 429MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote "Outperform" if you believe VSAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSAR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/19/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?